How to use Valganciclovir to prevent infection in organ transplant patients

Valganciclovir (Valganciclovir) is an oral antiviral drug that is a prodrug of ganciclovir (Ganciclovir) and can be rapidly converted into the active ingredient, ganciclovir, in the body. It inhibits the DNA polymerase activity of cytomegalovirus (CMV) and blocks virus replication, thereby achieving the purpose of preventing and treating CMV infection. Among organ transplant patients, CMV infection is a common and serious complication, which may cause graft rejection, increased immunosuppression and organ function damage. Therefore, Vancevir plays an important role in preventing CMV infection after transplantation.

In prophylactic use, Vancevir is usually started orally immediately after transplantation, especially in CMV high-risk patients (e.g., donor CMV positive, recipient CMV negative). The recommended dose is generally 900mg once a day, and the dose should be adjusted according to renal function. High-risk patients can continue to use it for 3 to 6 months to reduce the risk of early and late postoperative CMV infection. Doctors will develop an individualized dosage plan based on the patient's age, weight, kidney function and other parameters to ensure the drug's efficacy while reducing adverse reactions.

During the prevention process, patients need to regularly monitor hematological indicators and renal function, because Vancevir may cause leukopenia, thrombocytopenia, or abnormal renal function. Transplant patients are at higher risk of infection due to long-term use of immunosuppressants. Regular blood testing and viral load monitoring are crucial to evaluate efficacy and adjust medication. If serious side effects occur, the doctor may temporarily stop the medication or adjust the dose, and provide supportive care.

In addition, medication compliance with Vancevir is very important. Patients should strictly follow the doctor's instructions to take medication every day, and should not skip doses or increase or decrease the dose at will. In terms of food, Vancevi can be taken with or on an empty stomach, but taking it with food can reduce the incidence of gastrointestinal discomfort. Through standardized, continuous and individualized preventive medication, organ transplant patients can effectively reduce the risk of CMV infection and related complications, ensuring the stability of transplanted organ function and long-term quality of life.

Reference materials:https://www.drugs.com/